Comparing Ilumya vs Skyrizi
| Ilumya (tildrakizumab) | Skyrizi (risankizumab) |
|
|---|
| Ilumya (tildrakizumab) | Skyrizi (risankizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ilumya is administered by subcutaneous injection every 12 weeks (after an initial loading dose) and may be used to reduce inflammation associated with psoriasis but it needs to be administered by a... View more |
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Related suggestions Popular comparisons
|
|||||||||||||||
| More about Ilumya (tildrakizumab) | More about Skyrizi (risankizumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Ilumya has an average rating of 6.6 out of 10 from a total of 8 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 25% reported a negative effect. |
Skyrizi has an average rating of 8.0 out of 10 from a total of 57 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Ilumya side effects |
View all Skyrizi side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Ilumya prices |
View all Skyrizi prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
552 hours |
672 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 186 drugs are known to interact with Ilumya:
|
A total of 187 drugs are known to interact with Skyrizi:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
March 20, 2018 |
April 23, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.